Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide dose-escalation study in metastatic melanoma or metastatic Merkel cell carcinoma
NL-OMON40385Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- May 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pasireotide LAR in melanoma and Merkel cell carcinoma (MCC), sponsored by Novartis. Primary endpoint: Safety during first 8 weeks of pasireotide subcutaneous treatment. Planned start May 2014; status: withdrawn.
02
Drugs
pasireotide LAR
03
Conditions
melanomaMerkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NL-OMON40385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40385.